EPG Wealth Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$597K Sell
4,282
-169
-4% -$23.7K 0.16% 137
2025
Q4
$546K Buy
4,451
+3
+0.1% +$365 0.15% 141
2025
Q3
$494K Sell
4,448
-179
-4% -$20.3K 0.14% 143
2025
Q2
$513K Buy
4,627
+89
+2% +$9.47K 0.15% 141
2025
Q1
$509K Sell
4,538
-105
-2% -$10.8K 0.14% 163
2024
Q4
$429K Buy
4,643
+28
+0.6% +$2.52K 0.11% 171
2024
Q3
$387K Buy
+4,615
New +$352K 0.1% 178
2024
Q2
Sell
-5,082
Closed -$339K 198
2024
Q1
$372K Buy
5,082
+4
+0.1% +$308 0.09% 195
2023
Q4
$373K Sell
5,078
-582
-10% -$45.3K 0.1% 185
2023
Q3
$424K Sell
5,660
-6,304
-53% -$485K 0.13% 159
2023
Q2
$922K Buy
11,964
+184
+2% +$14.7K 0.27% 96
2023
Q1
$977K Buy
+11,780
New +$976K 0.31% 84
2020
Q2
Sell
-410
Closed -$30K 377
2020
Q1
$30K Buy
410
+267
+187% +$18.4K 0.02% 340
2019
Q4
$9K Buy
+143
New +$9.31K 0.01% 436

Other funds holding GILD

EPG Wealth Management's GILD Position: Q1 2026 in Review

EPG Wealth Management reduced its Gilead Sciences (GILD) stake by 3.8% in Q1 2026, selling an estimated $23.7K and leaving 4,282 shares worth $597K. The position accounts for 0.16% of the portfolio, ranked #137.

EPG Wealth Management first reported a position in GILD in Q4 2019 and has held it in 14 quarters since. The position peaked at $977K in Q1 2023. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • EPG Wealth Management held 4,282 shares of Gilead Sciences worth $597K as of Q1 2026.
  • EPG Wealth Management sold 169 Gilead Sciences shares in Q1 2026, an estimated $23.7K.
  • Gilead Sciences made up 0.16% of EPG Wealth Management's portfolio in Q1 2026, its #137 holding.
  • EPG Wealth Management first reported a position in Gilead Sciences in Q4 2019 and has held it in 14 quarters since.
  • EPG Wealth Management's Gilead Sciences position peaked at $977K in Q1 2023.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on EPG Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.